Pain Management Therapeutics

Pain Management Therapeutics Market Reaches $ 107.3 Billion Mark Pain Management Therapeutics Market (By Drug Class: NSAIDs, Opioids, Anesthetics, Antidepressants, Anticonvulsants, and Others; By Indication: Arthritic Pain, Neuropathic Pain, Chronic Back Pain, Post-Operative Pain, Cancer Pain, and Others; By Distribution Channel: Online Pharmacy, Retail Pharmacy, and Hospital Pharmacy) - Global Industry Analysis, Market Size, Share, Growth, Trends, Regional Outlook and Forecasts, 2021 - 2030

Share This Article

The pain management therapeutics market is expected to exhibit a CAGR of 4.3% from 2021 to 2030 and is projected to reach US$ 107.3 Billion by 2030, according to a 2021 study by Precedence Research, the Canada based market insight company.

The report contains 150+ pages with detailed analysis. The study provides the overall revenue of the global pain management therapeutics market from 2017 to 2030, considering 2020 as the base year and 2030 as the forecast year.

The global pain management therapeutics market research report gives a brief summary of definitions, size analysis, and place of production, sales, applications, types, and major players/key vendors of the pain management therapeutics industry. The report presents fresh perspectives on opportunities and challenges in a significantly transformed post-COVID-19 marketplace. This research study also integrates Industry Chain analysis and Porter’s Five Forces Analysis. Further, this report offers a competitive scenario that comprises collaborations, market concentration rate and expansions, mergers & acquisitions undertaken by companies.

We customize your report according to your research need. REQUEST CUSTOMIZED COPY OF REPORT (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/customization/1224

Growth Factors:

Factors such as increasing geriatric population, rising number of accidents worldwide, growing prevalence of chronic disorders, rise in per-capita healthcare expenditure, increasing number of surgeries, constant approvals for new easy-to-use and effective medications, increasing cases of cancer in developing regions, and growing research and development expenditure are propelling the pain management therapeutics market expansion across the globe. Additional aspects that are estimated to fuel this industry are strong product pipeline of major manufacturers and technological innovations. A constant rise in the cases of chronic disorders throughout the world is pushing the business to grow at a rapid pace. Early detection of ailment raises the chances for a decreased mortality rate. According to the American Cancer Society, around 1.76 million new cancer cases were diagnosed in 2019 and more than 606,000 cancer deaths reported in the United States alone. The number of elderly persons is also on the rise globally. According to the World Health Organization, the geriatric population is projected to hit 1.5 billion by the year 2040, which will represent around 16% of the entire world population.

Growing investment in the research and development activities aimed at improving the efficiency of existing therapy options along with developing new treatments is driving the market globally. The short-term as well as long-term strategies of leading biotech and pharma companies play a vital role in determining market trends. Short term policies aim at tackling patenting concerns and display an immediate effect on the market. Whereas, long term policies focus on upgrading R&D, focused treatment approaches, and unified network representations.

Report Highlights:

  • Among the drug class segment, NSAIDs dominated the overall market in 2020. High efficiency and ease of availability are the major reason for high market share of NSAIDs in pain management therapeutics.
  • The neuropathic pain segment accounted for the largest revenue within the indication segment with more than 32% share in 2020. Factors such as large patient pool and technological innovations drive the growth of interventional study. Chronic back pain and cancer pain indications are projected to grow at significant rate in the forecast time-frame.
  • Retail pharmacy accounted for the largest revenue in the distribution channel segment. High use of over-the-counter drugs for pain management is the key reason for high market share of retail pharmacies.
  • Pfizer, Teva Pharmaceutical, and AstraZeneca accounted for a significant share of the global pain management therapeutics market.

Top Players Contending in the Market:

The key companies are aiming towards advanced innovations and are predictable to dominate the target market. Foremost players inspiring in the global pain management therapeutics market are as follows:

  • Teva Pharmaceutical
  • Pfizer
  • Abbott
  • Mallinckrodt Pharmaceuticals
  • Endo International
  • GlaxoSmithKline
  • AstraZeneca
  • Depomed
  • Merck
  • Novartis

Market Segmentation

By Drug Class

  • NSAIDs
  • Opioids
  • Anesthetics
  • Antidepressants
  • Anticonvulsants
  • Others

By Indication

  • Arthritic Pain
  • Neuropathic Pain
  • Chronic Back Pain
  • Post-Operative Pain
  • Cancer Pain
  • Others

By Distribution Channel

  • Online Pharmacy
  • Retail Pharmacy
  • Hospital Pharmacy

Regional Segmentation

  • North America (U.S. and Canada)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Some of the key highlights covered in the report include:

Market Demand-Supply Analysis – The report covers detailed insights into demand and supply forces prevailing in the global pain management therapeutics market. It examines trends and factors influencing demand for pain management therapeutics globally and gauges the impact of the same on the production.

Pricing Analysis – The report presents an exclusive pricing analysis. It compares pricing strategies adopted by the leading market players and identifies the most remunerative strategies.

Market Segmentation – The report segments the global market in terms of diverse criteria. It identifies the leading segment within each category and identifies growth drivers and restraints affecting growth across each segment.

Regional Analysis – The report segments the market in terms of North America, Europe, Latin America, Asia Pacific, and Rest of the World in terms of region. It has chapters exclusively dedicated to analyzing growth trends across each region. It identifies growth drivers as well challenges affecting demand for pain management therapeutics across the world.

Competitive Analysis – Some of the leading market players are profiled in the report on pain management therapeutics. The report offers an estimation of share individually help by the market players and determines the impact of some of their popular strategies.

COVID-19 Impact Analysis – This chapter is exclusively dedicated to gauging how the market has evolved or will develop in the post-pandemic era.

Growth Recommendations – In the end, the report presents valuable recommendations to ready businesses for unforeseen challenges in the near future.

Why should you invest in this report?

If you are aiming to enter the global pain management therapeutics market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for pain management therapeutics are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Pain Management Therapeutics Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Pain Management Therapeutics Market

5.1. Covid-19: Pain Management Therapeutics Industry Impact
5.2. Pain Management Therapeutics Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Pain Management Therapeutics Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Pain Management Therapeutics Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Pain Management Therapeutics Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Growing prevalence of chronic disorders
6.1.1.2. Increasing geriatric population
6.1.2. Market Restraints
6.1.2.1. Side-effects associated with some pain management medications
6.1.3. Market Opportunities
6.1.3.1. Growing research and development expenditure
6.1.3.2. Technological advancements

Chapter 7. Global Pain Management Therapeutics Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Pain Management Therapeutics Market Revenue by Market Players (2016 -2019)
7.1.1.2. Pain Management Therapeutics Market Revenue Market Share by Market Players (2016 -2019)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Drug Class Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Pain Management Therapeutics Market, By Drug Class

8.1. Pain Management Therapeutics Market, by Drug Class, 2017 – 2030
8.1.1. NSAIDs
8.1.1.1. Market Revenue and Forecast (2017 – 2030)
8.1.2. Opioids
8.1.2.1. Market Revenue and Forecast (2017 – 2030)
8.1.3. Anesthetics
8.1.3.1. Market Revenue and Forecast (2017 – 2030)
8.1.4. Antidepressants
8.1.4.1. Market Revenue and Forecast (2017 – 2030)
8.1.5. Anticonvulsants
8.1.5.1. Market Revenue and Forecast (2017 – 2030)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2017 – 2030)

Chapter 9. Global Pain Management Therapeutics Market, By Indication

9.1. Pain Management Therapeutics Market, by Indication, 2017 – 2030
9.1.1. Arthritic Pain
9.1.1.1. Market Revenue and Forecast (2017 – 2030)
9.1.2. Neuropathic Pain
9.1.2.1. Market Revenue and Forecast (2017 – 2030)
9.1.3. Chronic Back Pain
9.1.3.1. Market Revenue and Forecast (2017 – 2030)
9.1.4. Post-Operative Pain
9.1.4.1. Market Revenue and Forecast (2017 – 2030)
9.1.5. Cancer Pain
9.1.5.1. Market Revenue and Forecast (2017 – 2030)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2017 – 2030)

Chapter 10. Global Pain Management Therapeutics Market, By Distribution Channel

10.1. Pain Management Therapeutics Market, by Distribution Channel, 2017 – 2030
10.1.1. Online Pharmacy
10.1.1.1. Market Revenue and Forecast (2017 – 2030)
10.1.2. Retail Pharmacy
10.1.2.1. Market Revenue and Forecast (2017 – 2030)
10.1.3. Hospital Pharmacy
10.1.3.1. Market Revenue and Forecast (2017 – 2030)

Chapter 11. Global Pain Management Therapeutics Market, Regional Estimates and Trend Forecast

11.1. North America
11.1.1. Market Revenue Forecast by Drug Class(2017 – 2030)
11.1.2. Market Revenue Forecast by Indication(2017 – 2030)
11.1.3. Market Revenue Forecast by Distribution Channel (2017 – 2030)
11.1.4. U.S
11.1.4.1. Market Revenue Forecast (2017 – 2030)
11.1.5. Canada
11.1.5.1. Market Revenue Forecast (2017 – 2030)
11.2. Europe
11.2.1. Market Revenue Forecast by Drug Class (2017 – 2030)
11.2.2. Market Revenue Forecast by Indication (2017 – 2030)
11.2.3. Market Revenue Forecast by Distribution Channel (2017 – 2030)
11.2.4. UK
11.2.4.1. Market Revenue Forecast (2017 – 2030)
11.2.5. Germany
11.2.5.1. Market Revenue Forecast (2017 – 2030)
11.2.6. France
11.2.6.1. Market Revenue Forecast (2017 – 2030)
11.2.7. Rest of EU
11.2.7.1. Market Revenue Forecast (2017 – 2030)
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Drug Class (2017 – 2030)
11.3.2. Market Revenue Forecast by Indication (2017 – 2030)
11.3.3. Market Revenue Forecast by Distribution Channel (2017 – 2030)
11.3.4. China
11.3.4.1. Market Revenue Forecast (2017 – 2030)
11.3.5. India
11.3.5.1. Market Revenue Forecast (2017 – 2030)
11.3.6. Japan
11.3.6.1. Market Revenue Forecast (2017 – 2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue Forecast (2017 – 2030)
11.4. LATAM
11.4.1. Market Revenue Forecast by Drug Class (2017 – 2030)
11.4.2. Market Revenue Forecast by Indication (2017 – 2030)
11.4.3. Market Revenue Forecast by Distribution Channel (2017 – 2030)
11.4.4. Brazil
11.4.4.1. Market Revenue Forecast (2017 – 2030)
11.4.5. Rest of LATAM
11.4.5.1. Market Revenue Forecast (2017 – 2030)
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Drug Class (2017 – 2030)
11.5.2. Market Revenue Forecast by Indication (2017 – 2030)
11.5.3. Market Revenue Forecast by Distribution Channel (2017 – 2030)
11.5.4. GCC
11.5.4.1. Market Revenue Forecast (2017 – 2030)
11.5.5. North Africa
11.5.5.1. Market Revenue Forecast (2017 – 2030)
11.5.6. South Africa
11.5.6.1. Market Revenue Forecast (2017 – 2030)
11.5.7. Rest of MEA
11.5.7.1. Market Revenue Forecast (2017 – 2030)

Chapter 12. Company Profiles

12.1. Teva Pharmaceutical
12.1.1. Company Overview, Business Information, Regional Presence
12.1.2. Product Portfolio Analysis
12.1.2.1. Product Details, Specification, Distribution Channel
12.1.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.1.4. Recent Developments and Strategies
12.2. Pfizer
12.2.1. Company Overview, Business Information, Regional Presence
12.2.2. Product Portfolio Analysis
12.2.2.1. Product Details, Specification, Distribution Channel
12.2.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.2.4. Recent Developments and Strategies
12.3. Abbott
12.3.1. Company Overview, Business Information, Regional Presence
12.3.2. Product Portfolio Analysis
12.3.2.1. Product Details, Specification, Distribution Channel
12.3.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.3.4. Recent Developments and Strategies
12.4. Mallinckrodt Pharmaceuticals
12.4.1. Company Overview, Business Information, Regional Presence
12.4.2. Product Portfolio Analysis
12.4.2.1. Product Details, Specification, Distribution Channel
12.4.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.4.4. Recent Developments and Strategies
12.5. Endo International
12.5.1. Company Overview, Business Information, Regional Presence
12.5.2. Product Portfolio Analysis
12.5.2.1. Product Details, Specification, Distribution Channel
12.5.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.5.4. Recent Developments and Strategies
12.6. GlaxoSmithKline
12.6.1. Company Overview, Business Information, Regional Presence
12.6.2. Product Portfolio Analysis
12.6.2.1. Product Details, Specification, Distribution Channel
12.6.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.6.4. Recent Developments and Strategies
12.7. AstraZeneca
12.7.1. Company Overview, Business Information, Regional Presence
12.7.2. Product Portfolio Analysis
12.7.2.1. Product Details, Specification, Distribution Channel
12.7.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.7.4. Recent Developments and Strategies
12.8. Depomed
12.8.1. Company Overview, Business Information, Regional Presence
12.8.2. Product Portfolio Analysis
12.8.2.1. Product Details, Specification, Distribution Channel
12.8.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.8.4. Recent Developments and Strategies
12.9. Merck
12.9.1. Company Overview, Business Information, Regional Presence
12.9.2. Product Portfolio Analysis
12.9.2.1. Product Details, Specification, Distribution Channel
12.9.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.9.4. Recent Developments and Strategies
12.10. Novartis
12.10.1. Company Overview, Business Information, Regional Presence
12.10.2. Product Portfolio Analysis
12.10.2.1. Product Details, Specification, Distribution Channel
12.10.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.10.4. Recent Developments and Strategies

Chapter 13. Appendix

13.1. About Us
13.2. Glossary of Terms

Purchase This Premium Research Report @ https://www.precedenceresearch.com/checkout/1224

About Us

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semiconductors, chemicals, automotive, and aerospace & defence, among different ventures, present globally.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://precedenceresearchnews.wordpress.com

Follow us on LinkedIn | Twitter | Facebook

Precedence Research

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

View all posts by Precedence Research →